Mesoblast posts Q4 Ryoncil net revenue of US$36 million
MESO•Debt and trial update
The company drew US$50 million from a five-year facility to extinguish all maturing debt obligations.
Mesoblast also commenced a registrational trial to extend Ryoncil into adults with steroid-refractory acute GvHD, with up to 40 U.S. sites planned.
Ryoncil revenue and cash spending
Mesoblast posted Ryoncil net revenue of US$36 million for the quarter ended June 30, 2026, and US$115 million for the first full year after FDA approval.
Second-half Ryoncil net revenue totaled US$66.5 million, while full-year net operating cash spend was US$43.8 million.
Second-half operating cash spend was US$13.4 million, and cash on hand was US$103 million at June 30, 2026.
